One DNMT inhibitor, 5-aza-2′-deoxycytidine (DAC), is an antitumor agent approved by the FDA for the treatment of myelodysplastic syndrome (MDS)26. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.